Image : https://letstalkrespiratory.com/wp-content/uploads/2020/12/thumb-1600x720-c-center.png

Lynn Elsey, Thomas Pantin, Leanne-Jo Holmes, Gael Tavernier, Stephen J Fowler

European Respiratory Journal 2021; DOI: 10.1183/13993003.01313-2021

Abstract

Almost a third of our patients with severe asthma did not have continued benefit from mepolizumab in the second year of treatment. Those with a sustained response had lower blood eosinophils and better asthma control questionnaire scores prior to starting mepolizumab.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Lynn Elsey and Leanne Holmes report payments for presentations, advisory boards and speakers fees from Astra Zeneca, GSK, Teva, Chiesi, Sanofi, Novartis; support to attend ERS congress, ATS conference and BTS winter meeting from Astra Zeneca, Teva, GSK, Novartis; outside the submitted work.

Conflict of interest: Thomas Pantin reports support to attend ERS congress BTS winter meeting from Chiesi, Sanofi, GSK; outside the submitted work.

Conflict of interest: Leanne-Jo Holmes has nothing to disclose.

Conflict of interest: Gael Tavernier has nothing to disclose.

Conflict of interest: Stephen J Fowler reports grants from Boehinger Ingelheim; speaker fees payments from Boehinger Ingelheim, Astra Zeneca, Teva, Chiesi, GSK, Novartis; support to attend ERS congress, ATS conference and BTS winter meeting from Chiesi, Sanofi, GSK, Astra Zeneca.

• Received May 7, 2021.
• Accepted September 26, 2021.

• Copyright ©The authors 2021. For reproduction rights and permissions contact permissions@ersnet.org